AdAlta is busy working towards a return on its investment in AD-214 and on building the foundations for future growth via its “east to west” cell therapy strategy, a strategy that is getting plenty of attention from both the company’s investor base and potential partners in Asia. CEO and Managing Director, Tim Oldham recently spoke with Tony Locantro of Alto Capital about his confidence in the near term potential for deals for both AD-214 and the cell therapy strategy. | Listen to the interview here: https://lnkd.in/gGZ8Cnzu
AdAlta Ltd’s Post
More Relevant Posts
-
Learn from global experts across academia, industry, and regulatory sectors in The Principles and Applications of Cell Therapy Biomanufacturing, Characterization, and Regulatory virtual course. Enhance your expertise with essential best practices and insights into the dynamic field of cell therapy. Learn More: https://buff.ly/48odEmK
-
-
Understanding the key ingredients to bring your cell therapy to market is crucial to achieving success. By starting with the end result in mind, you can avoid late phase CGT challenges. Discover how we helped 35+ global cell therapy clients. https://okt.to/irRCQL #celltherapymanufacturing #cdmo #cgt
-
🔬 Driving Breakthroughs in Molecular Interaction Analysis | Empowering Life Science Discoveries with Label-Free Technology | 🧪 🧬
Sadik Kassim shares what motivates him to do the work that has advanced cell therapy development to a point that seemed impossible only a decade ago. Watch the series finale of 'Pioneers and visionaries of cell therapy': https://lnkd.in/gVUXxUcZ #celltherapy #cellandgenetherapy #genomicmedicine #CART
-
Join Dawn Maier, Hannah W. Song, William Lloyd, PhD, CPI, and me tomorrow for a discussion on the benefits of using negative selection in cell therapy. Don’t miss out on this insightful conversation!
It’s not too late to join us tomorrow, September 10 at 1 PM ET to learn more about the use cases and benefits of negative selection. Hear our experts discuss how untouched cells could revolutionize cell therapy by providing healthier cells at scale. https://hubs.li/Q02P0-jf0 #thepositivesofnegativeselection #bettertcells #cellisolation #negativeselectionatscale
-
-
Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy https://lnkd.in/g2TyeCQX
-
-
Discover how you could accelerate your cell therapy development using an integrated, closed-loop screening system in this Technology digest, created in partnership with Sartorius >>> https://hubs.ly/Q02LHzxS0
Technology digest: Mitigating cell culture variability with robust screening of raw materials
-
What are the current emerging trends in allogeneic cell therapy? Dive into our latest update to learn more about investor interest, technological advancements and the commercial drivers that are transforming the allogeneic cell therapy landscape: https://ow.ly/ba7s30sFboq #SyneosHealth ft. Samvar Shah, Harry Bickerstaffe, Gursharan Batra
-
-
Sadik Kassim shares what motivates him to do the work that has advanced cell therapy development to a point that seemed impossible only a decade ago. Watch the series finale of 'Pioneers and visionaries of cell therapy': https://lnkd.in/ejVjaUGG #celltherapy #cellandgenetherapy #genomicmedicine #CART
-
Gain valuable insights from cell therapy experts on CAR detection advancements, current challenges in CAR-T and CAR-NK therapy development, and exciting innovations on the horizon. Learn more here: https://bit.ly/3X3ELkI
-
-
Sadik Kassim shares what motivates him to do the work that has advanced cell therapy development to a point that seemed impossible only a decade ago. Watch the series finale of 'Pioneers and visionaries of cell therapy': https://lnkd.in/efrWCnxJ #celltherapy #cellandgenetherapy #genomicmedicine #CART
